Fierce Pharma

NOVEMBER 12, 2024

The cash will be used to grow the company’s research and production footprint in the States by the end of 2026, generating more than 1,000 new jobs along the way. . | AstraZeneca on Tuesday revealed that it’s adding $2 billion more to its current outlay in the U.S., representing a total capital investment of $3.5

Manufacturing 173

Manufacturing 173

Fierce Pharma

SEPTEMBER 28, 2023

Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business. Riding on the growth of long-acting antiretroviral therapy Cabenuva, GSK is laying out a more optimistic vision for its overall HIV business.

Sales 227

Sales 227

Fierce Pharma

OCTOBER 7, 2024

GSK’s ViiV healthcare unit is countering rival HIV drugmaker Gilead’s recent global access moves with its own pledge to make at least 2 million doses of its long-acting pre-exposure prophylaxis (Pr | The long-acting HIV PrEP maker pledged to make at least 2 million more doses available for low-and middle-income countries in 2025 and 2026.

Healthcare 183

Healthcare Healthcare 183

Fierce Pharma

NOVEMBER 4, 2024

The deal is expected to extend Nektar's cash runway into 2026 and help the company hone its development of novel immunology drugs.

Manufacturing 180

Manufacturing Sales 180

Fierce Pharma

SEPTEMBER 3, 2024

28, 2026. Reddy’s formulations production plant, China’s National Medical Products Administration has suspended the import, sale and use of the Indian drugmaker’s atomoxetine hydrochloride capsules for ADHD. In addition, Dr. Reddy’s is prohibited from taking part in China’s drug procurement scheme through Feb.

Manufacturing 229

Manufacturing Sales Medical 229

Fierce Pharma

MARCH 18, 2024

As bluebird bio works to make the most of three gene therapy launches, cash-flow concerns have been looming over the drugmaker. | The funding should extend bluebird bio's cash runway through the first quarter of 2026 as it advances three gene therapy launches.

224

224

Fierce Pharma

JUNE 10, 2024

Colorado’s Prescription Drug Affordability Review Board (PDAB) isn’t waiting for the Inflation Reduction Act (IRA) to lower prices on certain drugs starting in 2026. After the review board unanimously agreed that Stelara is "unaffordable," the drug could be subject to an upper payment limit in the state.

Prescription 180

Prescription Marketing 180

Fierce Pharma

OCTOBER 9, 2023

billion) for exclusive rights to distribute the shingles shot in China from 2024 through 2026. GSK has forged a partnership with vaccine powerhouse Chongqing | GSK has forged a partnership with vaccine powerhouse Chongqing Zhifei Biological Products to distribute Shingrix in China. Zhifei will pay £2.5 billion ($3.05

Distribution 270

Distribution 270

Fierce Pharma

SEPTEMBER 5, 2023

The case was filed Friday in New Jersey federal court, three days after the CMS revealed that Novartis’ heart failure treatment Entresto was among 10 drugs subject to price negotiations in 2026.

Biopharma 283

Biopharma Government 283

Fierce Pharma

JANUARY 4, 2024

The Seattle-based CDMO has unveiled its plan to construct a four-story complex, which will cover 20,000 square meters (215,000 square feet) and is expected to become operational in 2026.

Manufacturing 247

Manufacturing 247

Fierce Pharma

SEPTEMBER 12, 2023

28, 2026. The deal clears “all pending claims” and tees up a potential Dasynoc launch on Sept. 1, 2024, or potentially earlier under certain circumstances. The Sprycel patents in question aren’t due to expire until Sept.

FDA 274

FDA Pharma 274

Fierce Pharma

MARCH 7, 2024

By Eisai’s 2026 fiscal year—which ends in March 2027—the company figures its Alzheimer's disease drug Leqembi can bring home 290 billion Japanese yen (nearly $2 billion) in global revenues. Come fiscal year 2032, those sales could potentially swell to a whopping 1.3 trillion yen ($8.8 billion).

Sales 201

Sales 201

PharmaVoice

OCTOBER 23, 2024

As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.

98

98

Fierce Pharma

OCTOBER 27, 2023

In August, Imbruvica was one of the 10 drugs identified by the CMS that will be subject to price negotiations in 2026. . | Sales of AbbVie and Johnson & Johnson’s leukemia blockbuster Imbruvica are taking a hit from BeiGene’s Brukinsa. But what about the impact of the Inflation Reduction Act?

Sales 236

Sales 236

Fierce Pharma

DECEMBER 14, 2023

Ahead of 2026’s Medicare drug price negotiations, the White House is getting ready to crack down on companies who’ve raised the costs of their medications faster than the rate of inflation.

Medical 194

Medical 194

MedCity News

OCTOBER 3, 2024

The firm predicts in-progress lab construction will decline to pre-pandemic levels by 2026. Laboratory construction has waned in the past two years due to the end of the pandemic and an economic slowdown, according to a new report from CBRE.

Biopharma 105

Biopharma Pharma 105

Pharmaceutical Commerce

AUGUST 16, 2024

By 2026, the first 10 drugs for individuals with Part D coverage—whose medications are mainly used to treat cancer, diabetes, and heart disease—will see discounts off of list prices ranging from 38-79%.

Medical 98

Medical 98

MedCity News

AUGUST 15, 2024

The first 10 drugs selected for Medicare price negotiations now have new prices set to take effect in 2026. Industry observers note that most of these drugs are older products facing generic competition soon, so greater industry impact will come as the program expands to more drugs in years to come.

Competition 121

Competition Biopharma Pharma 121

PharmaVoice

NOVEMBER 5, 2024

Rallybio is headed into a mid-stage trial with enough cash through 2026, but the cyclical market has made the journey difficult.

Marketing 52

Marketing 52

pharmaphorum

MAY 3, 2024

AI-powered home healthcare model from Cera could save NHS and UK £1bn in 2026 if adopted nationwide, says new study

Healthcare 85

Healthcare Healthcare 85

MedCity News

MAY 15, 2023

The royalty deal extends uniQure’s cash runway into 2026. By selling partial royalties to approved hemophilia gene therapy Hemgenix, uniQure gains immediate cash to support its pipeline, including a Huntington’s disease gene therapy already in the clinic.

Biopharma 109

Biopharma Pharma 109

pharmaphorum

NOVEMBER 12, 2024

AstraZeneca plans to invest a whopping $3.5

Biopharma 76

Biopharma Sales Manufacturing Pharma 76

PharmaVoice

AUGUST 16, 2024

The final negotiations slash drug prices between 38% and 79% for Medicare’s 2026 calendar year.

59

59

PharmaTech

SEPTEMBER 15, 2023

According to a press release, the implications go to the extent that within the next 10 years, more than 50% of approved drugs will involve AI in their development and/or manufacturing.

Manufacturing 52

Manufacturing 52

Pharmacy Times

AUGUST 15, 2024

The new prices are expected to go into effect for patients with Medicare Part D on January 1, 2026.

Patients 59

Patients 59

Scott Burrows

JULY 5, 2022

By 2026, industry experts expect EV sales to quadruple from 2020,… As an insurance and financial speaker with strong ties to the industry, I have not seen such interesting—and positive—developments in years. For example, according to Statista the sales of electric vehicles are on the verge of explosion.

Insurance 98

Insurance Sales 98

PharmExec

AUGUST 29, 2023

Lawsuit comes amid announcement of the first 10 drugs eligible for negotiated prices in 2026.

98

98

Pharmaceutical Technology

JULY 20, 2023

The centre is planned for completion in 2026, along with plans to build a $400m biologics manufacturing plant.

Manufacturing 74

Manufacturing 74

Pharmaceutical Technology

NOVEMBER 8, 2023

The company’s cash reduction measures are expected to extend its cash runway into 2026.

64

64

World of DTC Marketing

MAY 9, 2022

Online Ad Stats : Social media advertising budgets are expected to grow 11.76% annually by 2026. billion by 2026 , is still a new frontier of the digital world, an all but lawless Wild West where a few major industry players have seized territory for their gain. Online ad fraud is costing pharma millions.

Pharma 208

Pharma Media Marketing Sales 208

Clear Pivot

SEPTEMBER 22, 2022

billion by 2026 , so take the steps to create a successful medtech marketing strategy now as the industry is still growing. However, while your product is the backbone of your success, you must also successfully market it to buyers. Revenue from the medical technology industry is projected to reach $644.20

Marketing 76

Marketing Competition Medical Healthcare 76

Pharmaceutical Technology

SEPTEMBER 23, 2022

It will expire on 24 November 2026, and the paediatric exclusivity lasts until 24 May 2027. Additionally, Merck has signed patent litigation settlement deals with various generic firms, permitting them to offer generic versions of Januvia and Janumet to the US market in May 2026, or before under specific conditions.

Food and Drug Administration 69

Food and Drug Administration FDA Food Marketing 69

European Pharmaceutical Review

JULY 10, 2023

billion in 2026. Given their short shelf-life, there is a need for methods that generate more rapid results for emerging advanced therapy medicinal products (ATMPs) such as cell and gene therapies. Currently, there are more than 2,000 active clinical trials for cell and gene therapies, 1 with the market expected to grow from $8.6

Pharmaceutical products 98

Pharmaceutical products Manufacturing Medicine Pharmaceutical 98

European Pharmaceutical Review

SEPTEMBER 12, 2024

Production is expected to begin in 2026. Lilly noted that these include engineers, scientists, quality assurance professionals and operations personnel, totalling 450 employees at the facility. Kinsale site Additionally, expansion of Lilly’ Kinsale facility will be funded by an $800 million investment.

Manufacturing 105

Manufacturing Medicine Engineering Pharmaceutical 105

European Pharmaceutical Review

NOVEMBER 12, 2024

To boost AstraZeneca’s research and manufacturing footprint by the end of 2026, it is dedicating $3.5 billion of capital investment in the US. Of this amount, $2 billion will generate over 1,000 new jobs, the company added.

Manufacturing 59

Manufacturing Biopharma Healthcare Healthcare 59

pharmaphorum

SEPTEMBER 30, 2022

That challenged the ‘708 patent – which expires in November 2026 – as well as one other (No. Viatris could still take its cases further, but for now Merck has retained market exclusivity for Januvia, Janumet, and Janumet XR until at least 2026.

Marketing 59

Marketing Sales Competition FDA 59

Pharmacy Times

AUGUST 30, 2023

Any new prices established after negotiations will be effective on January 1, 2026.

52

52